
 
 
 
 
 
 
 
 
 
 1. A Chinese Hamster Ovary (CHO) cell which is capable of higher protein sialylation compared to a wild type Chinese Hamster Ovary cell, such as in the presence of functional GnT 1, in which the CHO cell is obtainable by selection with Ricinus communis agglutinin I (RCA-I). 
 
 
 2. A CHO cell according to Claim 1, which: 
 (i) comprises a mutation in the GnT 1 gene, such as selected from the following mutations at the specified position of a GnT 1 sequence (GenBank accession number: AF343963): (a) a C to T transition at position 1015; 
 (b) a G to C transversion at position 1300; 
 (c) an A to C transversion at position 638; 
 (d) a C to G transversion at position 784; 
 (e) a T to A transversion at position 811; (f) an insertion at position 706 resulting in a frame shift from position 236 of the encoded amino acid sequence; 
 (g) a C to T transition at position 1015; (h) a G to A transition at position 246; (i) a G to A transition at position 258; Q) an A to T transversion at position 859, or which 
 (ii) expresses a GnT 1 protein comprising one or more of the following mutations at the specified position of a GnT 1 sequence (GenBank accession number: AF343963): 
 (a) Ala to Pro at position 434; (b) Asp → Ala at position 213; 
 (c) Arg — >Gly at position 262; 
 (d) Tip → Arg at position 271 ;  (e) frame shift from position 236 resulting from an insertion at, position 706 of an encoding GnT 1 nucleic acid sequence; 
 (f) Gln→STOP at position 339; 
 (g) Trp→STOP at position 82; (h) Trp→STOP at position 86; 
 (i) Lys→STOP at position 287. 
 
 
 3. A CHO cell according to Claim 1 or 2, in which the GnT 1 gene comprises a GnT 1 nucleic acid sequence shown in SEQ ID NO: 1, or which expresses a GnT 1 protein as shown in SEQ ID NO: 2. 
 
 
 4. A CHO cell according to Claim 1, 2 or 3, in which the CHO cell comprises: 
 (a) a nucleic acid sequence encoding a protein of interest such as a recombinant protein of interest, such as erythropoietin (EPO) or interferon-γ (IFN-γ); or 
 (b) nucleic acid sequence encoding functional GnT 1 ; or 
 (c) a nucleic acid sequence encoding the protein of interest and a nucleic acid sequence encoding functional GnT 1 comprised in one expression vector, such as stably transfected into the CHO cell. 
 
 
 5. A CHO cell line comprising a CHO cell according to any preceding claim. 
 
 
 6. A CHO cell line comprising a JWl 52 cell line (deposited at ATCC under the Budapest Treaty as accession number PTA-9657), a JW80 cell line, a JW36 cell line, a KFCl 5002 cell line, a KFC15071 cell line, a KFC5008 cell line, a JW152 cell line, a KFC5026 cell line, a KFC20011 cell line or a KFC 15047 cell line. 
 
 
 7. A CHO cell or a CHO cell line according to any preceding claim, which is adapted to suspension culture. 
 
 
 8. A recombinant protein expressed by a CHO cell or CHO cell line according to any preceding claim, such as comprising erythropoietin (EPO) or interferon-γ (IFN-γ). 
 
 
 9. A recombinant protein according to Claim 8, which comprises a pKa of 4 or less, 3.5 or less, 3 or less, 2.5 or less or 2 or less or a Z-number of greater than 150, such as greater  than 160, greater than 170, greater than 180, such as greater than 190, greater than 200, greater than 210, such as greater than 220 or greater than 230, or both. 
 
 
 10. A method of expressing a recombinant protein, the method comprising introducing a nucleic acid encoding the protein into a CHO cell according to any of Claims 1 to 7, allowing the protein to be expressed from the CHO cell or a descendent thereof, and optionally purifying the protein, the method further optionally comprising introducing or stably transfecting a nucleic acid encoding functional GnT 1 into the CHO cell such as in the form of an expression vector comprising a nucleic acid sequence encoding the protein and a nucleic acid sequence encoding functional GnT 1. 
 
 
 11. A nucleic acid comprising a sequence shown in SEQ ID NO: 1, or a sequence comprising a GnT 1 sequence together with a mutation set out in Column 2 of Table Dl, or a variant, homologue, derivative or fragment thereof. 
 
 
 12. A polypeptide comprising a sequence as shown in SEQ ID NO: 2, or a sequence comprising a GnT 1 sequence together with a mutation set out in Column 3 of Table Dl, or a variant, homologue, derivative or fragment thereof. 
 
 
 13. A method of providing a CHO cell or cell line, the method comprising culturing CHO cells in the presence of Ricinus communis agglutinin I (RCA-I) and selecting cells which survive the culture, in which for example: 
 (a) the CHO cells are exposed to RCA-I at a concentration of between O.lμg/ml to lOOμg/ml, for example up to 50 μg/ml or up to 20μg/ml, such as lOμg/ml or 5μg/ml; or 
 (b) the CHO cells are exposed RCA-I for a period of from an hour, a few hours (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12), overnight, to a few days, such as 2 days or 3 days, such as overnight. 
 
 
 14. A method according to Claim 13, further comprising selecting cells which do not react with RCA-I in an agglutination test. 
 
 
 15. A CHO cell or CHO cell line obtainable by a method according to Claim 13 or 14.   
 
 
 16. A CHO cell, cell line, recombinant protein, method, nucleic acid or polypeptide substantially as hereinbefore described with reference to and as shown in Figures 1 to 12 of the accompanying drawings.  
 
 
 
 
 
 
 
 
 
 
